Wolverine Asset Management LLC Purchases New Holdings in Emergent BioSolutions Inc. (NYSE:EBS)

Wolverine Asset Management LLC purchased a new stake in shares of Emergent BioSolutions Inc. (NYSE:EBS) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 136,333 shares of the biopharmaceutical company’s stock, valued at approximately $1,303,000.

Other hedge funds also recently added to or reduced their stakes in the company. State Street Corp lifted its position in Emergent BioSolutions by 864.7% during the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock valued at $15,960,000 after acquiring an additional 1,713,200 shares during the last quarter. Oak Hill Advisors LP purchased a new stake in Emergent BioSolutions during the third quarter valued at approximately $9,296,000. Assenagon Asset Management S.A. lifted its position in Emergent BioSolutions by 3.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 766,537 shares of the biopharmaceutical company’s stock valued at $7,328,000 after acquiring an additional 24,985 shares during the last quarter. Geode Capital Management LLC lifted its position in Emergent BioSolutions by 4.6% during the third quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company’s stock valued at $4,861,000 after acquiring an additional 25,776 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its position in Emergent BioSolutions by 41.7% during the fourth quarter. New York State Common Retirement Fund now owns 306,286 shares of the biopharmaceutical company’s stock valued at $2,928,000 after acquiring an additional 90,113 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

EBS has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Emergent BioSolutions in a research report on Tuesday, January 21st. Benchmark upped their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, StockNews.com upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a research note on Monday, February 17th.

Emergent BioSolutions Stock Down 1.3 %

NYSE:EBS opened at $7.74 on Friday. The firm has a market capitalization of $419.44 million, a P/E ratio of -1.89 and a beta of 1.62. Emergent BioSolutions Inc. has a 1-year low of $1.82 and a 1-year high of $15.10. The company’s fifty day moving average price is $9.66 and its 200-day moving average price is $9.07. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.